Shares of SRPT opened at $126.27 on Thursday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics has a 52 week low of $102.15 and a 52 week high of $173.25. The company's 50 day moving average price is $122.10 and its 200 day moving average price is $131.36. The company has a market capitalization of $12.06 billion, a PE ratio of 101.02 and a beta of 0.77.
In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now directly owns 22,840 shares of the company's stock, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of the business's stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. This represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company's stock.
A number of hedge funds have recently made changes to their positions in the company. Teachers Retirement System of The State of Kentucky bought a new stake in Sarepta Therapeutics during the second quarter worth about $4,771,000. Simplify Asset Management Inc. raised its position in Sarepta Therapeutics by 84.6% in the 3rd quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company's stock valued at $24,105,000 after purchasing an additional 88,474 shares during the last quarter. Geode Capital Management LLC boosted its stake in Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock worth $211,910,000 after purchasing an additional 44,306 shares in the last quarter. Summit Partners Public Asset Management LLC boosted its stake in Sarepta Therapeutics by 547.9% in the third quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company's stock worth $17,250,000 after purchasing an additional 116,800 shares in the last quarter. Finally, Larson Financial Group LLC grew its holdings in shares of Sarepta Therapeutics by 1,649.8% during the third quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company's stock worth $1,093,000 after purchasing an additional 8,249 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Sarepta Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.
While Sarepta Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.